TrialCancer2025

A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.

Jayesh Desai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.